<DOC>
	<DOCNO>NCT02241499</DOCNO>
	<brief_summary>In trial , patient histologically proven adenocarcinoma esophagus esophagogastric junction noneligible surgery chemoradiation curative intent include . Primary objective determine rate improvement dysphagia palliative short course hypofractionated radiotherapy ( 5 x 4 Gy ) follow chemotherapy consist oxaliplatin fluorouracil . The rate improvement dysphagia evaluate 5 grade dysphagia score , positive change least 1 score consider improvement .</brief_summary>
	<brief_title>Palliative Short-course Hypofractionated Radiotherapy Followed Chemotherapy Adenocarcinoma Esophagus Esophagogastric Junction Trial - Phase II Clinical Trial Protocol .</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Patients histologically proven adenocarcinoma esophagus esophagogastric junction noneligible surgery chemoradiation curative intent Any T , N M Age : 18 year old WHO performance status ≤ 2 Life expectancy &gt; 3 month Dysphagia score &gt; 0 Adequate laboratory finding : hemoglobin &gt; 90 g/L , absolute neutrophil count 1.0 10 9/L , platelet ≥ 75 x 10 9/L , bilirubin ≤ 1.5 x upper limit normal ( ULN ) , alanine aminotransferase ( ALAT ) ≤ 5 x ULN , creatinine ≤ 1.5 x ULN Fertile men woman must use effective mean contraception Signed write informed concent The patient must able comply protocol Prior treatment selfexpanding metal stent ( SEMS ) , radiotherapy chemotherapy present disease Clinically significant ( i.e . active ) cardiovascular disease e.g . myocardial infarction ( ≤ 6 month ) unstable angina , New York Heart Association ( NYHA ) grade IIIIV congestive heart failure Severe pulmonary disease e.g . pulmonary fibrosis Symptomatic peripheral neuropathy great grade 1 ( CTCAE v. 4.0 ) Known hypersensitivity content study drug Pregnancy ( positive pregnancy test ) and/or breast feed Any serious uncontrolled illness opinion investigator make undesirable patient enter trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Digestive System Diseases</keyword>
	<keyword>Esophageal cancer</keyword>
	<keyword>Intestinal Neoplasms</keyword>
	<keyword>Gastrointestinal Neoplasms</keyword>
	<keyword>Digestive System Neoplasms</keyword>
	<keyword>Endoscopic response</keyword>
	<keyword>Fluorouracil</keyword>
	<keyword>Metabolic response</keyword>
	<keyword>Oxaliplatin</keyword>
	<keyword>Radiotherapy</keyword>
</DOC>